CA3049738A1 - Interaction between c-peptides and elastin receptor, a model for understanding vascular disease - Google Patents

Interaction between c-peptides and elastin receptor, a model for understanding vascular disease Download PDF

Info

Publication number
CA3049738A1
CA3049738A1 CA3049738A CA3049738A CA3049738A1 CA 3049738 A1 CA3049738 A1 CA 3049738A1 CA 3049738 A CA3049738 A CA 3049738A CA 3049738 A CA3049738 A CA 3049738A CA 3049738 A1 CA3049738 A1 CA 3049738A1
Authority
CA
Canada
Prior art keywords
seq
peptide
elastin
binding
motif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3049738A
Other languages
English (en)
French (fr)
Inventor
Gert Wensvoort
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resiliun BV
Original Assignee
Resiliun BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resiliun BV filed Critical Resiliun BV
Publication of CA3049738A1 publication Critical patent/CA3049738A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3049738A 2017-02-06 2018-02-05 Interaction between c-peptides and elastin receptor, a model for understanding vascular disease Pending CA3049738A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17154889 2017-02-06
EP17154889.4 2017-02-06
PCT/EP2018/052824 WO2018141970A1 (en) 2017-02-06 2018-02-05 Interaction between c-peptides and elastin receptor, a model for understanding vascular disease

Publications (1)

Publication Number Publication Date
CA3049738A1 true CA3049738A1 (en) 2018-08-09

Family

ID=57995050

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3049738A Pending CA3049738A1 (en) 2017-02-06 2018-02-05 Interaction between c-peptides and elastin receptor, a model for understanding vascular disease
CA3051293A Pending CA3051293A1 (en) 2017-02-06 2018-02-05 Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3051293A Pending CA3051293A1 (en) 2017-02-06 2018-02-05 Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use

Country Status (8)

Country Link
US (4) US20200087374A1 (enExample)
EP (3) EP3577462B1 (enExample)
JP (2) JP7438757B2 (enExample)
AU (2) AU2018216033B2 (enExample)
CA (2) CA3049738A1 (enExample)
ES (1) ES2927977T3 (enExample)
SG (2) SG11201906943VA (enExample)
WO (2) WO2018141969A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6982395B2 (ja) * 2017-03-16 2021-12-17 三洋化成工業株式会社 インターロイキン１０の産生量増加剤
WO2019104391A1 (en) * 2017-12-01 2019-06-06 St Vincent's Institute Of Medical Research Type 1 diabetes treatment
CA3149581A1 (en) * 2019-08-30 2021-03-04 Gert Wensvoort Q-er peptide
JP6895148B1 (ja) * 2020-03-31 2021-06-30 クラシエホールディングス株式会社 冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定する判定用マーカー、冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定する判定方法、及び冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定するための判定用キット
CN111704653B (zh) * 2020-06-08 2023-10-03 深圳市图微安创科技开发有限公司 靶向于纤连蛋白衍生肽的抑制剂多肽化合物及其用途
EP4225352A4 (en) * 2020-10-08 2024-01-10 Dr. Mary Morris & Associates, LLC Methods and compositions for the treatment and prevention of type 1 diabetes
CN112345770A (zh) * 2020-11-06 2021-02-09 苏州大学附属第一医院 弹性蛋白降解肽作为腹膜透析患者血管钙化标志物的应用
KR102718109B1 (ko) * 2021-10-01 2024-10-17 (주)케어젠 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도
EP4412633A1 (en) * 2021-10-05 2024-08-14 Biotempt B.V. Angiogenic control, preferably combined with glycaemic control
AU2023308137A1 (en) 2022-07-12 2025-01-30 Biotempt B.V. Treating conditions with hypoglycemia associated with hyperinsulinemia.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
US6734289B2 (en) 2001-03-29 2004-05-11 The University Of Chicago Gastrokines and derived peptides including inhibitors
AU2003228382A1 (en) * 2002-03-27 2003-10-13 University Of Utah Research Foundation Elastin prevents occlusion of body vessels by vascular smooth muscle cells
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
GB0412174D0 (en) 2004-06-01 2004-06-30 Creative Peptides Sweden Ab Degradation-resistant analogues of pro-insulin c-peptide
WO2008118387A2 (en) * 2007-03-23 2008-10-02 Wayne State University Erythrocyte atp-release modulators
WO2011038301A2 (en) * 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
KR20140128314A (ko) * 2012-02-01 2014-11-05 에프. 호프만-라 로슈 아게 다중특이적 결합제의 결합 파트너 검출 방법
DK2626704T3 (en) * 2012-02-08 2016-02-22 Mehmet Ali Soylemez Diagnosis of pancreatic diabetes in patients with normal blood leucocyte counts using procalcitonin
JP5945063B2 (ja) * 2012-04-12 2016-07-05 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 慢性心不全が疑われる患者における有害事象の予後
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
CN104937421B (zh) * 2013-01-08 2018-01-19 斯弗因高泰克有限公司 生长激素的禁食水平作为心血管风险的预测标志物
US20140274891A1 (en) * 2013-03-15 2014-09-18 Health Diagnostic Laboratory, Inc. Method of generating an index score for mbl deficiency to predict cardiodiabetes risk
CN104371003B (zh) 2013-08-15 2025-09-02 上海市第一人民医院 预防和治疗炎症的小分子多肽及其应用
SG11201607487UA (en) * 2014-03-21 2016-10-28 Sanofi Aventis Deutschland New markers for the assessment of the risk for development of a cardiovascular disorder

Also Published As

Publication number Publication date
EP4421088A2 (en) 2024-08-28
WO2018141970A1 (en) 2018-08-09
US20220009988A1 (en) 2022-01-13
AU2018216033B2 (en) 2021-10-07
US20250123275A1 (en) 2025-04-17
EP3577462C0 (en) 2024-04-17
SG11201906939XA (en) 2019-08-27
JP2024056838A (ja) 2024-04-23
SG11201906943VA (en) 2019-08-27
AU2018216033A1 (en) 2019-08-15
WO2018141969A1 (en) 2018-08-09
US20240027431A1 (en) 2024-01-25
AU2018215245B2 (en) 2024-07-11
EP4421088A3 (en) 2024-12-04
JP7438757B2 (ja) 2024-02-27
ES2927977T3 (es) 2022-11-14
EP3577462B1 (en) 2024-04-17
EP3570875B1 (en) 2022-07-06
EP3577462A1 (en) 2019-12-11
AU2018215245A1 (en) 2019-07-25
JP2020507623A (ja) 2020-03-12
EP3570875A1 (en) 2019-11-27
CA3051293A1 (en) 2018-08-09
US20200087374A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
AU2018215245B2 (en) Interaction between C-peptides and elastin receptor, a model for understanding vascular disease
US7776563B2 (en) Methods for identifying agents for treating cardiovascular disease using inhibition of myeloperoxidase binding
CN102459348A (zh) 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白
CA2505250A1 (en) Acetylated hmgb1 protein
Janssens et al. Natural nitration of CXCL12 reduces its signaling capacity and chemotactic activity in vitro and abrogates intra-articular lymphocyte recruitment in vivo
AU2019202918B2 (en) Agonist of spexin-based galanin type 2 receptor and use thereof
WO2011071280A2 (ko) 세포내 타겟 결합용 바이포달 펩타이드 바인더
CN101848926B (zh) 能够结合免疫球蛋白的肽
JP2005527235A (ja) デフェンシン：抗ウイルス剤の使用
JP2010229093A (ja) 新規ＣｈｅｍｅｒｉｎＲアゴニスト
AU2019386379B2 (en) DPEP-1 binding agents and methods of use
Faitar et al. EVI5 is a novel centrosomal protein that binds to α-and γ-tubulin
EP1577320B1 (en) Peptides derived from human BPLP protein, polynucleotides coding for said peptides and antibodies directed against said peptides
RU2662973C2 (ru) Пептидомиметики
US20220023383A1 (en) Pharmaceutical compositions and methods targeting wnt pathway proteins
WO2014014819A2 (en) Methods of treating glucose metabolism disorders
KR101156992B1 (ko) 혈압 강하 활성을 가지는 펩티드
SEQUENCE-CONTAINING et al. OR03 P682
Zhang et al. Two Chromogranin A-Derived Peptides Induce Calcium Entry in Human
JP2018043934A (ja) 神経変性疾患タンパク質の異常凝集を伴って発症する神経疾患に対する予防又は治療剤、及び上記予防又は治療剤のスクリーニング方法
WO2014014816A2 (en) Methods of treating glucose metabolism disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230130

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240806

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250131

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250131

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250131

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260319